Status: Recruiting

A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy

This is an open label, multi-center study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of RAG-01 in patients with NMIBC who have failed BCG therapy.

Participants needed: 72

Trial details

Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Ractigen Therapeutics.Updated: Sep 11, 2025Locations: 3

Eligibility criteria

Ability to understand the study and have signed the informed consent form; [+6]

Subject who is allergy to RAG-01 or similar products; [+19]

Status: Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation

This is a Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects with Amyotrophic Lateral Sclerosis (ALS) with Superoxide Dismutase Type 1 (SOD1) Gene Mutation

Participants needed: 32

Trial details

Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Ractigen Therapeutics.Updated: Jan 8, 2025Locations: 3

Eligibility criteria

Voluntarily consents to participate in this study and provides written informed... [+5]

Documented p.F21C SOD1 mutation. [+4]

Clinical trials

A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation